LEXICON PHARMACEUTICALS PROVIDES AN UPDATE ON THE SOTAGLIFLOZIN TYPE 2 DIABETES PROGRAMGlobeNewsWire • 03/19/20
LEXICON PHARMACEUTICALS ANNOUNCES ADDITIONAL DATA ON TELOTRISTAT ETHYL’S ANTIPROLIFERATIVE EFFECTS IN PATIENTS WITH CARCINOID SYNDROMEGlobeNewsWire • 03/13/20
Lexicon Pharmaceuticals, Inc. (LXRX) CEO Lonnel Coats on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/12/20
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 03/12/20
Lexicon Pharmaceuticals Announces Real-World Data on Telotristat Ethyl’s Antiproliferative Effects in Patients With Carcinoid SyndromeGlobeNewsWire • 01/24/20
Lexicon Pharmaceuticals Announces Topline Phase 3 Data for Sotagliflozin in Type 2 DiabetesGlobeNewsWire • 12/20/19
Lexicon Pharmaceuticals Completes Safety Review of Initial Safety Run-in Cohort of TELE-ABC Study, a Phase 2 Clinical Study of Telotristat Ethyl in Biliary Tract CancerGlobeNewsWire • 12/03/19
Why Roku, Ollie's Bargain Outlet Holdings, and Lexicon Pharmaceuticals Slumped TodayThe Motley Fool • 12/02/19
Lexicon Pharmaceuticals stock slides 15% premarket after FDA denies appeal of decision relating to diabetes drugMarket Watch • 12/02/19
Are Investors Undervaluing Lexicon Pharmaceuticals (LXRX) Right Now?Zacks Investment Research • 11/14/19
Lexicon Pharmaceuticals, Inc (LXRX) CEO Lonnel Coats on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/09/19
Lexicon Pharmaceuticals (LXRX) Q3 Earnings and Revenues Beat EstimatesZacks Investment Research • 11/07/19
Lexicon Pharmaceuticals (LXRX) to Report Q3 Results: Wall Street Expects Earnings GrowthZacks Investment Research • 10/31/19
Lexicon Pharmaceuticals Announces Poster Presentations at the NANETS Annual Multidisciplinary NET Medical SymposiumGlobeNewsWire • 10/02/19
Are Options Traders Betting on a Big Move in Lexicon Pharmaceuticals (LXRX) Stock?Zacks Investment Research • 09/23/19